Alport Kidney Gene Therapy Moves Closer to First Trials

Alport kidney gene therapy took a step toward human testing this week, after a London company presented laboratory and animal results for a candidate designed to replace a missing collagen protein in the kidney. The data were presented at ASN Kidney Week in Denver, according to Purespring Therapeutics, the company behind the treatment. The candidate, called PS-003, is aimed at X-linked Alport syndrome, an inherited condition in which the kidney lacks a working copy of a gene that builds part of its filtration barrier. No approved therapy targets the underlying cause of the condition, so a treatment that restores the missing protein would address the disease at its source rather than managing damage after it appears.

The laboratory work for this Alport kidney gene therapy centred on podocytes, the specialised kidney cells that produce the filtration barrier. In human podocytes, the candidate produced a full-length version of the missing collagen protein, with no detectable by-products, according to the company. That protein then formed functional three-part collagen structures, and those structures were secreted in a dose-dependent manner. The protein was also detected in the filtration-barrier-like matrix of a three-dimensional model of the glomerulus, the tiny filtering unit of the kidney, which the researchers read as support for moving the approach toward clinical testing.

Animal testing of the Alport kidney gene therapy gave the same broad picture. In a mouse model of the X-linked form of the condition, a single intravenous dose produced durable expression of the protein at the filtration barrier and rescued two related collagen proteins that were largely undetectable in untreated animals. Studies in minipigs, a model often used to bridge laboratory work and human trials, showed gene delivery to the kidney, with the gene message detected in most filtering units examined. No treatment-related safety concerns were observed, even at doses well above the highest planned clinical dose, according to the company.

The scale of the condition was set out in a second presentation built from a genetic analysis of more than a million genomes drawn from populations in the United States, the United Kingdom, Europe and Japan. Using a conservative counting method that included only known disease-causing variants and variants predicted to switch a gene off, the analysis estimated that 150,000 American patients have moderate or severe forms of the X-linked condition. The same analysis found more than eighteen hundred distinct disease-causing variants across the three genes involved, with most patients carrying rare or unique variants and the most common variants differing by geography. A later-onset variant accounts for a substantial share of adult-onset cases in the United States and Europe, a pattern the researchers said suggests genetic testing may be underused in older patients with suspected disease.

Why Alport kidney gene therapy matters for patients

For patients, Alport kidney gene therapy matters because the course of the X-linked condition is often fast and unforgiving. It typically appears in males during childhood or early adulthood with persistent blood in the urine, followed by protein in the urine, high blood pressure and declining kidney function. Many patients reach end-stage kidney disease in their mid-twenties, according to the company, and from that point dialysis or a kidney transplant becomes the usual course. Current care can slow damage, but it does not replace the missing protein, which is why families and clinicians have waited for a treatment aimed at the cause.

Patient groups welcomed the Alport kidney gene therapy results while keeping the timeline in view. The head of a United Kingdom patient charity said people living with the condition still lack treatment options that address its underlying cause, and described genetically targeted approaches moving toward the clinic as an important step. The executive director of an American patient organisation said wider genetic testing in kidney disease is already revealing how often the condition goes undiagnosed, and argued that a clearer picture of its true scale matters for education, research funding and the development of new therapies.

What happens next for Alport kidney gene therapy

The next step for Alport kidney gene therapy is a filing the company plans to submit for first-in-human studies next year. That filing would be the formal step that allows regulators to review the laboratory and animal package before any patient receives the treatment. The platform behind the candidate is already in clinical development for a different kidney condition, IgA nephropathy, and the company describes its earlier candidate as the first kidney-targeted gene therapy to have been given to patients. That history does not prove the new candidate will work in people, but it gives regulators and clinicians a prior human experience with the delivery approach to weigh alongside the new data.

Several questions remain open for Alport kidney gene therapy, and they will decide whether the laboratory result becomes a medicine. Human safety, the right dose, how long any benefit lasts, and whether restored protein production slows kidney decline in patients all still need testing. The company has not published pricing, trial locations or eligibility criteria, and none of those details can be assumed from a preclinical package. For now, the result stands as a tested biological target with animal safety data behind it, rather than a treatment patients can request. Readers can follow the original reporting on the results in FirstWord Pharma coverage of the Purespring announcement.